# Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

> **NCT02163720** · — · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 101 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Yondelis®-Caelyx®

## Key facts

- **NCT ID:** NCT02163720
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-10
- **Primary completion:** 2017-03
- **Final completion:** 2018-09-18
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2020-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163720, "Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02163720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*